MARKET OUTLOOK Renal inflammation associated with systemic lupus erythematosus (SLE), also known as lupus nephritis (LN), is among the most serious manifestations of the disease. Presently, no…
Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen / Novartis…
Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen / Novartis…
The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…
With over a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and many more in the pipeline, the treatment journey for U.S. MS patients…
Despite heart failure with preserved ejection fraction (HFpEF) accounting for approximately half of all chronic heart failure (CHF) cases, and despite our improved understanding of the…
Osteoarthritic (OA) pain is the second-largest segment of the chronic pain therapy market and is expected to grow, driven by an aging population and the increasing prevalence of obesity. Yet a…
Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g.,…
The wet AMD market is dominated by three therapies—Roche / Genentech / Novartis’s Lucentis, approved for wet AMD, Roche / Genentech / Chugai’s Avastin, approved for cancer but commonly…
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9…
Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of supporting evidence from clinical trials. ACE inhibitors or AIIRA/ARBs, beta…
The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanezumab and Regeneron / Teva / Mitsubishi Tanabe…
In the United States a plethora of pharmacological treatments from an array of drug classes are available to patients with major depressive disorder (MDD), a highly drug-treated condition. Though…
Drug treatment of glaucoma focuses on reducing / controlling IOP and preserving visual function. Given the availability of therapies from several drug classes (e.g., PGAs, beta blockers, FDCs),…
Dyslipidemia is an important modifiable risk factor for cardiovascular disease, which is one of the leading causes of death globally. Statins continue to dominate treatment of dyslipidemia, driven…